ANGO - AngioDynamics Inc Stock Price, Fair Value and News

6.25USD-0.01 (-0.16%)Delayed as of 22 Apr 2024, 12:01 pm ET

Market Summary

USD6.25-0.01

Delayedas of 22 Apr 2024, 12:01 pm

-0.16%

ANGO Alerts

1 major insider buys recently.

ANGO Stock Price

View Fullscreen

ANGO RSI Chart

ANGO Valuation

Market Cap

250.7M

Price/Earnings (Trailing)

-1.3

Price/Sales (Trailing)

0.77

EV/EBITDA

-1.01

Price/Free Cashflow

-12.4

ANGO Price/Sales (Trailing)

ANGO Profitability

EBT Margin

-61.53%

Return on Equity

-87.96%

Return on Assets

-59.23%

Free Cashflow Yield

-8.06%

ANGO Fundamentals

ANGO Revenue

Revenue (TTM)

324.0M

Rev. Growth (Yr)

-6.85%

Rev. Growth (Qtr)

-4.92%

ANGO Earnings

Earnings (TTM)

-192.4M

Earnings Growth (Yr)

-1.9K%

Earnings Growth (Qtr)

-546.3%

Breaking Down ANGO Revenue

52 Week Range

6.1911.38

(Low)(High)

Last 7 days

-1.9%

Last 30 days

11.8%

Last 90 days

6.8%

Trailing 12 Months

-29.4%

How does ANGO drawdown profile look like?

ANGO Financial Health

Current Ratio

2.29

Debt/Equity

0.23

Debt/Cashflow

-0.35

ANGO Investor Care

Shares Dilution (1Y)

2.09%

Diluted EPS (TTM)

-4.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	324.0M	0	0	0
2023	334.7M	338.8M	335.9M	329.5M
2022	306.1M	316.2M	320.8M	327.9M
2021	272.5M	291.0M	297.8M	303.3M
2020	277.0M	264.2M	268.3M	271.1M
2019	265.6M	270.6M	272.7M	272.8M
2018	282.4M	261.7M	260.7M	264.1M
2017	356.1M	349.6M	326.5M	304.0M
2016	351.2M	353.9M	358.2M	358.0M
2015	359.9M	356.5M	353.2M	350.3M
2014	360.1M	360.1M	359.9M	359.9M
2013	318.1M	354.4M	358.1M	361.7M
2012	220.2M	221.8M	251.0M	281.5M
2011	215.7M	215.6M	218.5M	223.3M
2010	0	216.0M	215.9M	215.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AngioDynamics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	clemmer james c	bought	67,000	6.7	10,000	president and ceo
Feb 29, 2024	trowbridge stephen a	acquired	8,999	4.67	1,927	evp and cfo
Jul 21, 2023	helsel dave	sold (taxes)	-3,157	8.65	-365	svp global operations and r&d
Jul 21, 2023	campbell chad thomas	sold (taxes)	-3,416	8.65	-395	svp/gm, vascular access
Jul 21, 2023	clemmer james c	sold (taxes)	-29,167	8.65	-3,372	president and ceo
Jul 21, 2023	trowbridge stephen a	sold (taxes)	-5,769	8.65	-667	evp and cfo
Jul 21, 2023	centea scott	sold (taxes)	-2,205	8.65	-255	svp/gm, vit
Jul 21, 2023	piccinini laura	sold (taxes)	-3,572	8.65	-413	svp international
Jul 20, 2023	trowbridge stephen a	sold (taxes)	-6,266	8.74	-717	evp and cfo
Jul 20, 2023	campbell chad thomas	sold (taxes)	-3,137	8.74	-359	svp/gm, vascular access

Which funds bought or sold ANGO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Diversified Trust Co	sold off	-100	-133,044	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-91.53	-639,957	43,338	-%
Apr 16, 2024	Williams & Novak, LLC	unchanged	-	-	178,870	0.20%
Apr 15, 2024	Concurrent Investment Advisors, LLC	new	-	91,728	91,728	-%
Apr 12, 2024	Dynamic Advisor Solutions LLC	added	132	189,935	348,942	0.01%
Apr 05, 2024	CWM, LLC	reduced	-58.98	-6,000	3,000	-%
Apr 05, 2024	GAMMA Investing LLC	reduced	-84.1	-3,874	728	-%
Apr 04, 2024	MOODY NATIONAL BANK TRUST DIVISION	unchanged	-	-30,415	90,627	0.01%
Apr 03, 2024	Versant Capital Management, Inc	sold off	-100	-227	-	-%
Apr 03, 2024	WealthCollab, LLC	new	-	2,352	2,352	-%

Are Funds Buying or Selling ANGO?

Are funds buying ANGO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANGO

No. of Funds

ANGO Alerts

1 major insider buys recently.

Unveiling AngioDynamics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.69%	2,268,461	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	3.7%	1,489,108	SC 13G/A
Jan 23, 2024	blackrock inc.	12.7%	5,044,098	SC 13G/A
Jan 23, 2024	millennium management llc	4.6%	1,835,777	SC 13G/A
Jan 22, 2024	state street corp	2.53%	1,009,307	SC 13G/A
Oct 06, 2023	blackrock inc.	10.5%	4,161,884	SC 13G/A
Sep 12, 2023	millennium management llc	5.2%	2,055,247	SC 13G
Jul 05, 2023	victory capital management inc	3.68%	1,445,045	SC 13G/A
Feb 10, 2023	dimensional fund advisors lp	6.9%	2,687,481	SC 13G/A
Feb 09, 2023	vanguard group inc	7.11%	2,781,793	SC 13G/A

Recent SEC filings of AngioDynamics Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	10-Q	Quarterly Report
Apr 08, 2024	4	Insider Trading
Apr 04, 2024	8-K	Current Report
Apr 01, 2024	8-K	Current Report
Mar 22, 2024	UPLOAD	UPLOAD
Mar 06, 2024	CORRESP	CORRESP
Mar 04, 2024	4	Insider Trading
Feb 22, 2024	UPLOAD	UPLOAD
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	8-K	Current Report

Peers (Alternatives to AngioDynamics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.2B	40.1B	-3.77%	-2.76%	32.53	4.64	-8.12%	-17.45%
BDX	67.7B	19.5B	-1.53%	-10.57%	53.87	3.47	4.02%	-22.04%
ALGN	22.5B	3.9B	-9.16%	-15.16%	50.45	5.81	3.42%	23.09%
BAX	20.0B	14.8B	-5.62%	-8.72%	7.55	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.49%	17.01%	32.33	2.64	4.97%	18.89%
HSIC	9.1B	12.3B	-5.22%	-14.61%	21.9	0.74	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.90%	-39.13%	-12.81	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.41%	-25.34%	-47.02	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-2.66%	12.41%	-562.64	9.32	33.86%	89.83%
PDCO	2.3B	6.6B	-4.93%	-3.92%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-14.38%	-20.49%	-1.83	0.39	7.73%	-1066.14%
ANIK	383.7M	166.7M	0.86%	-5.21%	-4.64	2.3	6.67%	-456.34%
ANGO	250.7M	324.0M	11.81%	-29.38%	-1.3	0.77	-3.19%	-337.41%
APYX	45.7M	52.3M	-28.65%	-55.25%	-2.44	0.87	17.61%	19.28%
AEMD	3.8M	3.7M	-10.98%	147.46%	-0.31	1.02	5.77%	8.23%

AngioDynamics Inc News

Latest updates

AngioDynamics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-4.9%	75,182,000	79,073,000	78,679,000	91,074,000	80,712,000	85,429,000	81,537,000	86,998,000	73,970,000	78,280,000	76,971,000	76,842,000	71,182,000	72,770,000	70,216,000	58,332,000	69,780,000	70,003,000	66,042,000	71,182,000	65,524,000
Gross Profit	-10.9%	35,861,000	40,262,000	40,060,000	46,359,000	40,504,000	45,078,000	42,305,000	46,455,000	38,583,000	40,555,000	40,139,000	42,320,000	38,530,000	40,174,000	35,764,000	30,212,000	40,299,000	41,544,000	38,217,000	41,332,000	38,163,000
Operating Expenses	354.1%	242,414,000	53,382,000	52,872,000	67,196,000	49,432,000	53,193,000	55,606,000	52,852,000	43,878,000	49,234,000	48,239,000	63,907,000	42,268,000	45,010,000	40,886,000	186,823,000	46,535,000	44,967,000	39,045,000	38,398,500	41,837,000
S&GA Expenses	-0.2%	25,405,000	25,464,000	27,368,000	26,293,000	25,406,000	26,007,000	26,543,000	26,833,000	20,416,000	23,606,000	24,446,000	23,820,000	19,607,000	20,174,000	17,705,000	18,207,000	20,934,000	20,113,000	19,380,000	20,775,500	18,385,000
R&D Expenses	-5.4%	8,189,000	8,658,000	7,941,000	7,860,000	6,852,000	6,838,000	8,333,000	7,866,000	7,280,000	8,199,000	7,394,000	9,104,000	8,565,000	9,712,000	9,009,000	7,231,500	8,395,000	7,764,000	6,292,000	6,893,000	6,915,000
EBITDA Margin	-950.1%	-0.53	0.06	0.08	-0.06	-0.02	-0.01	-0.01	0.00	-0.05	-0.05	-0.04	-0.03	-	-	-	-	-	-	-	-	-
Interest Expenses	26.2%	-394,000	-534,000	-119,000	901,000	736,000	684,000	381,000	185,000	173,000	174,000	156,000	185,000	226,000	235,000	215,000	235,000	166,000	41,000	465,000	1,410,000	1,442,000
Income Taxes	-173.1%	-12,004,000	16,430,000	-11,023,000	-398,000	-179,000	-565,000	-853,000	-455,000	-799,000	-512,000	-1,636,000	-2,471,000	-583,000	-905,000	-545,000	158,000	-824,000	-566,000	-116,000	-1,365,000	-773,000
Earnings Before Taxes	-1483.0%	-199,740,000	-12,618,000	34,861,000	-21,865,000	-9,664,000	-9,051,000	-13,857,000	-6,721,000	-5,757,000	-8,863,000	-8,608,000	-21,939,000	-4,127,000	-5,173,000	-4,813,000	-156,909,000	-6,533,000	-3,302,000	-1,391,000	1,388,500	-5,382,000
EBT Margin	-2083.5%	-0.62	-0.03	-0.02	-0.16	-0.12	-0.11	-0.11	-0.09	-0.15	-0.14	-0.13	-0.12	-	-	-	-	-	-	-	-	-
Net Income	-546.3%	-187,736,000	-29,048,000	45,884,000	-21,467,000	-9,485,000	-8,486,000	-13,004,000	-13,004,000	-4,958,000	-8,351,000	-6,972,000	-19,468,000	-3,544,000	-4,268,000	-4,268,000	-157,067,000	-5,709,000	-2,736,000	-1,275,000	58,873,000	796,000
Net Income Margin	-1286.0%	-0.59	-0.04	0.02	-0.15	-0.13	-0.12	-0.12	-0.11	-0.13	-0.13	-0.12	-0.11	-	-	-	-	-	-	-	-	-
Free Cashflow	-378.7%	-13,133,000	4,712,000	-26,690,000	14,898,000	704,000	6,218,000	-25,554,000	7,521,000	-9,897,000	810,000	-9,925,000	11,579,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-35.0%	325	500	494	533	543	558	558	553	543	554	556	561	582	589	584	594	732	725	690	836	778
Current Assets	6.2%	197	185	175	164	153	159	151	143	128	132	131	141	146	150	142	153	129	132	166	315	143
Cash Equivalents	28.8%	78.00	61.00	58.00	45.00	30.00	30.00	25.00	29.00	24.00	34.00	35.00	48.00	54.00	58.00	48.00	54.00	27.00	41.00	84.00	228	42.00
Inventory	-9.6%	58.00	64.00	60.00	55.00	64.00	63.00	58.00	51.00	48.00	48.00	49.00	49.00	49.00	50.00	53.00	60.00	55.00	50.00	45.00	40.00	52.00
Net PPE	-13.0%	37.00	43.00	43.00	44.00	46.00	46.00	46.00	45.00	44.00	43.00	41.00	37.00	30.00	30.00	29.00	28.00	28.00	28.00	25.00	24.00	41.00
Goodwill	-100.0%	-	159	159	159	200	201	201	201	201	202	201	201	201	201	201	201	359	12.00	348	348	424
Liabilities	7.9%	106	98.00	66.00	154	145	150	144	128	113	122	120	122	127	134	129	139	121	111	76.00	222	224
Current Liabilities	10.0%	86.00	78.00	57.00	84.00	70.00	74.00	66.00	74.00	49.00	54.00	52.00	58.00	50.00	46.00	40.00	51.00	49.00	57.00	47.00	73.00	53.00
Long Term Debt	-	-	-	-	50.00	-	-	-	25.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.00	6.00
Shareholder's Equity	-45.5%	219	401	428	378	398	408	414	424	430	432	436	439	455	454	455	455	610	614	614	615	554
Retained Earnings	-96.8%	-381	-194	-164	-210	-189	-179	-171	-158	-152	-147	-138	-131	-112	-108	-104	-100	57.00	62.00	65.00	66.00	8.00
Additional Paid-In Capital	0.5%	609	605	604	599	596	593	590	587	584	580	576	574	571	567	564	562	560	558	556	555	553
Shares Outstanding	0.5%	40.00	40.00	40.00	40.00	40.00	39.00	39.00	39.00	39.00	39.00	39.00	38.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	450	-	-	-	894	-	-	-	496	-	-	-	531	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-337.9%	-12,526	5,266	-25,899	15,954	1,370	7,499	-24,745	8,560	-8,791	1,941	-8,904	12,199	5,871	11,448	-5,425	3,880	-17,837	5,937	-6,534	25,012	8,342
Share Based Compensation	39.2%	2,612	1,877	4,144	2,981	1,803	3,350	3,024	2,903	2,352	3,008	2,429	2,227	2,147	2,387	1,864	1,594	1,772	2,242	1,984	2,130	2,378
Cashflow From Investing	1739.9%	29,404	-1,793	98,442	-1,528	-2,146	-2,496	-3,576	-3,773	-2,593	-3,849	-9,092	-9,144	-1,382	-1,361	-1,824	-1,479	-11,742	-48,583	-1,541	168,427	463
Cashflow From Financing	297.2%	694	-352	-59,590	-	941	103	24,376	329	966	942	5,446	-9,445	-8,022	-10.00	491	24,947	15,560	-	-135,749	-7,242	-10,081

ANGO Income Statement

2024-02-29

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Income Statement [Abstract]
Net sales	$ 75,182	$ 80,712	$ 232,934	$ 247,678
Cost of sales (exclusive of intangible amortization)	39,321	40,208	116,751	119,791
Gross profit	35,861	40,504	116,183	127,887
Operating expenses:
Research and development	8,189	6,852	24,788	22,023
Sales and marketing	25,405	25,406	78,237	77,956
General and administrative	10,578	8,839	30,723	29,775
Amortization of intangibles	3,287	4,739	10,474	14,384
Goodwill impairment	159,476	0	159,476	0
Change in fair value of contingent consideration	112	227	203	2,084
Acquisition, restructuring and other items, net	35,367	3,369	44,767	12,009
Total operating expenses	242,414	49,432	348,668	158,231
Gain on sale of assets	6,657	0	54,499	0
Operating loss	(199,896)	(8,928)	(177,986)	(30,344)
Other expense:
Interest income (expense), net	394	(736)	1,047	(1,801)
Other expense, net	(238)	0	(558)	(427)
Total other income (expense), net	156	(736)	489	(2,228)
Loss before income tax benefit	(199,740)	(9,664)	(177,497)	(32,572)
Income tax benefit	(12,004)	(179)	(6,597)	(1,597)
Net loss	$ (187,736)	$ (9,485)	$ (170,900)	$ (30,975)
Loss per share
Loss per share, basic (USD per share)	$ (4.67)	$ (0.24)	$ (4.26)	$ (0.79)
Loss per share, diluted (USD per share)	$ (4.67)	$ (0.24)	$ (4.26)	$ (0.79)
Weighted average shares outstanding
Basic weighted average shares outstanding (in shares)	40,234	39,509	40,098	39,436
Diluted weighted average shares outstanding (in shares)	40,234	39,509	40,098	39,436

ANGO Balance Sheet

2024-02-29

Consolidated Balance Sheets - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Current assets
Cash and cash equivalents	$ 78,451	$ 44,620
Accounts receivable, net of allowances of $2,560 and $2,150 respectively	49,475	52,826
Inventories	58,068	55,325
Prepaid expenses and other	10,913	4,617
Current assets held for sale	0	6,154
Total current assets	196,907	163,542
Property, plant and equipment, net	37,040	44,384
Intangible assets, net	81,570	111,144
Goodwill	0	159,238
Other assets	9,325	10,676
Non-current assets held for sale	0	43,653
Total assets	324,842	532,637
Current liabilities
Accounts payable	35,152	40,445
Accrued liabilities	30,963	26,617
Current portion of contingent consideration	9,500	14,761
Other current liabilities	10,259	2,002
Total current liabilities	85,874	83,825
Long-term debt	0	49,818
Deferred income taxes	5,917	12,813
Contingent consideration, net of current portion	0	4,535
Other long-term liabilities	14,353	3,350
Total liabilities	106,144	154,341
Commitments and contingencies (Note 14)
Stockholders' equity
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 40,794,533 and 39,981,422 shares issued and 40,424,533 and 39,611,422 shares outstanding at February 29, 2024 and May 31, 2023, respectively	385	382
Additional paid-in capital	608,588	599,206
Accumulated deficit	(381,755)	(210,855)
Treasury stock, 370,000 shares at February 29, 2024 and May 31, 2023, respectively	(5,714)	(5,714)
Accumulated other comprehensive income	(2,806)	(4,723)
Total Stockholders’ Equity	218,698	378,296
Total Liabilities and Stockholders' Equity	$ 324,842	$ 532,637

About AngioDynamics Inc

AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

CEO	Mr. James C. Clemmer
WEBSITE	angiodynamics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	815

AngioDynamics Inc Frequently Asked Questions

What is the ticker symbol for AngioDynamics Inc? What does ANGO stand for in stocks?

ANGO is the stock ticker symbol of AngioDynamics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AngioDynamics Inc (ANGO)?

As of Fri Apr 19 2024, market cap of AngioDynamics Inc is 250.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANGO stock?

You can check ANGO's fair value in chart for subscribers.

What is the fair value of ANGO stock?

You can check ANGO's fair value in chart for subscribers. The fair value of AngioDynamics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AngioDynamics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANGO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AngioDynamics Inc a good stock to buy?

The fair value guage provides a quick view whether ANGO is over valued or under valued. Whether AngioDynamics Inc is cheap or expensive depends on the assumptions which impact AngioDynamics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANGO.

What is AngioDynamics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, ANGO's PE ratio (Price to Earnings) is -1.3 and Price to Sales (PS) ratio is 0.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANGO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AngioDynamics Inc's stock?

In the past 10 years, AngioDynamics Inc has provided -0.08 (multiply by 100 for percentage) rate of return.